RESEARCH MONOGRAPH · KDC-MN-273

Toremifene

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

68/100

Tamoxifen analog that's basically a slightly modified clinical alternative with a marginally different profile

Toremifene is the SERM that most people forget exists, and that's mostly fair. Orion Pharmaceuticals developed it as a chlorinated tamoxifen analog in the 80s with the idea that the chlorine substitution would shift the agonist/antagonist balance and reduce the genotoxic concerns that some early work had flagged about tamoxifen metabolites. In practice the differences between toremifene and tamoxifen at the clinical level are modest.

The mechanism is the same SERM story: triphenylethylene scaffold, ER-alpha binding with mixed agonist/antagonist activity depending on tissue context, differential coactivator recruitment. The chlorine substitution does shift the metabolism somewhat (less CYP2D6 dependence than tamoxifen, more CYP3A4) and reduces the formation of some of the more reactive metabolites that the early genotoxicity concerns focused on. Whether that translates to a meaningfully different long-term safety profile is unclear; the magnitude of risk for the relevant rare events is small enough that head-to-head differentiation requires very large trials.

What we like is the metabolic profile difference. For research questions about how CYP2D6 polymorphism affects SERM pharmacodynamics, toremifene is a useful comparator to tamoxifen because the metabolic dependence is different. If you're studying the same biology with two different CYP-vulnerability profiles, that's a useful pair.

What we dont like is that for most research and clinical purposes there's no compelling reason to use toremifene over tamoxifen. The data base is much thinner, the cost is higher in most markets, and the differentiation isnt large enough to justify the choice unless you have a specific reason. The QT prolongation signal that emerged later in clinical experience is real and adds a cardiac safety consideration that tamoxifen doesnt have to the same degree.

The high-dose work in advanced prostate cancer (toremifene at much higher doses for gynecomastia and other indications, mostly explored by GTx with a fareston-related compound) is an interesting offshoot but never reached approval.

Sourcing is moderate. Off-patent in most markets, but generic availability is more limited than tamoxifen. The citrate salt is the standard. Research-grade material is available with appropriate QC.

Honest take: useful niche comparator, otherwise largely a tamoxifen alternative without compelling differentiation. Underdeveloped clinically; useful research tool in specific contexts.

Evidence: 70
Mechanism: 80
Reliability: 75
Safety: 72
Sourcing: 75
Value: 65
Signal: 55
Staying power: 55

Plain-language summary Intrigue 45 / 100

Toremifene (Fareston) is a chlorinated cousin of tamoxifen, approved in 1997 for postmenopausal metastatic breast cancer. It shares the same triphenylethylene scaffold and tissue-selective estrogen-receptor profile, with two practical differences: it is metabolized less by CYP3A4 (so fewer drug interactions) and produces a different metabolite mix (notably no endoxifen). Clinical efficacy in breast cancer is broadly similar to tamoxifen. It is used as an alternative when tamoxifen is poorly tolerated or when its drug interactions cause problems. Less common in the US than internationally. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Triphenylethylene SERM (tamoxifen analog)

A chlorinated triphenylethylene SERM analog of tamoxifen; alternative SERM in postmenopausal breast cancer.

Abstract

Toremifene (2-[4-[(Z)-4-chloro-1,2-diphenyl-1-buten-1-yl]phenoxy]-N,N-dimethylethanamine; CAS 89778-26-7; molecular formula C26H28ClNO; molecular weight 405.96) is a triphenylethylene SERM developed at Orion Pharma (Finland) and approved by the FDA in 1997 under the trade name Fareston. The compound is a chlorinated analog of tamoxifen, sharing the triphenylethylene scaffold and tissue-selective ER modulation profile. Pharmacokinetic differences from tamoxifen include reduced CYP3A4-dependent metabolism (decreasing some drug-drug interaction potential) and a different metabolite spectrum (notably absent the highly active endoxifen analog of tamoxifen). Approved for metastatic breast cancer in postmenopausal women with ER-positive or ER-unknown tumors. Off-label PCT use in athletes is documented. Plasma half-life is approximately 5 days. Adverse events parallel tamoxifen including thromboembolism and hot flashes. Used as a tamoxifen alternative in clinical and research contexts.

Mechanism of action

Triphenylethylene SERM with tissue-selective ER modulation. Reduced CYP3A4 metabolism compared to tamoxifen; different metabolite spectrum.

Reported research dose ranges

Clinical 60 mg in the published literature for breast cancer. Rodent studies 1 to 10 mg/kg.

References

Pyrhonen S, et al. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer. Br J Cancer 1997.
Ellmen J, Hakulinen P, et al. Toremifene: pharmacology and clinical experience. Cancer Treat Rev 1995.
Jain S, et al. Toremifene in breast cancer: a systematic review. Drug Discov Today 2014.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-273

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Toremifene

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs